BR112022024539A2 - Vírus sincicial respiratório vivo atenuado - Google Patents

Vírus sincicial respiratório vivo atenuado

Info

Publication number
BR112022024539A2
BR112022024539A2 BR112022024539A BR112022024539A BR112022024539A2 BR 112022024539 A2 BR112022024539 A2 BR 112022024539A2 BR 112022024539 A BR112022024539 A BR 112022024539A BR 112022024539 A BR112022024539 A BR 112022024539A BR 112022024539 A2 BR112022024539 A2 BR 112022024539A2
Authority
BR
Brazil
Prior art keywords
live
respiratory syncytial
atenuated
syncytial virus
viruses
Prior art date
Application number
BR112022024539A
Other languages
English (en)
Portuguese (pt)
Inventor
Collins Peter
Buchholz Ursula
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112022024539A2 publication Critical patent/BR112022024539A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022024539A 2020-06-05 2021-06-04 Vírus sincicial respiratório vivo atenuado BR112022024539A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063035617P 2020-06-05 2020-06-05
PCT/US2021/036030 WO2021248086A2 (en) 2020-06-05 2021-06-04 Live attenuated respiratory syncytial virus

Publications (1)

Publication Number Publication Date
BR112022024539A2 true BR112022024539A2 (pt) 2022-12-27

Family

ID=76708442

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024539A BR112022024539A2 (pt) 2020-06-05 2021-06-04 Vírus sincicial respiratório vivo atenuado

Country Status (10)

Country Link
US (1) US20230279362A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161567A2 (cg-RX-API-DMAC7.html)
JP (1) JP7888214B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230021115A (cg-RX-API-DMAC7.html)
CN (1) CN116568323A (cg-RX-API-DMAC7.html)
AU (1) AU2021285997A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185143A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022015398A (cg-RX-API-DMAC7.html)
WO (1) WO2021248086A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846455B2 (en) * 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
DE10020505A1 (de) * 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
BRPI0112276B8 (pt) * 2000-06-23 2021-05-25 The Government Of The Us Secretary Of Department Of Health And Human Services vírus sincicial respiratório (rsv) recombinante infeccioso e polinucleotídeo isolado contendo um genoma ou antigenoma de resv recombinante parcial ou completo
US20080142531A1 (en) 2004-06-25 2008-06-19 Simon Hem Jensen Container Body with an Integrated Handle
PL3511015T3 (pl) * 2012-04-13 2021-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetycznie stabilna żywa atenuowana szczepionka przeciw syncytialnemu wirusowi oddechowemu i jej wytwarzanie
CA2900713A1 (en) * 2013-02-08 2014-08-14 Steffen Mueller Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
EP3247388B1 (en) 2015-01-20 2025-09-10 The United States of America, as represented by The Secretary, Department of Health and Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
WO2017100759A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains with mutations in the m2-2 orf providing a range of attenuation phenotypes

Also Published As

Publication number Publication date
AU2021285997A1 (en) 2023-01-19
CA3185143A1 (en) 2021-12-09
JP2023529836A (ja) 2023-07-12
WO2021248086A2 (en) 2021-12-09
MX2022015398A (es) 2023-04-05
EP4161567A2 (en) 2023-04-12
CN116568323A (zh) 2023-08-08
JP7888214B2 (ja) 2026-07-13
KR20230021115A (ko) 2023-02-13
WO2021248086A3 (en) 2022-01-13
US20230279362A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
MX2022009429A (es) Composiciones para la inmunizacion contra virus respiratorios.
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
CO2018005229A2 (es) Vacuna de virus sincitial respiratorio
PH12018500855A1 (en) Herpes simplex virus vaccine
MX2018007860A (es) Vacunas recombinantes contra el zika.
CO7160021A2 (es) Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
MX2016016533A (es) Combinaciones inmunogenas.
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
IN2014MN01714A (cg-RX-API-DMAC7.html)
PH12022552084A1 (en) Vaccine against african swine fever virus infection
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
ZA202305129B (en) Recombinant hvt and uses thereof
WO2024191860A3 (en) Nucleic acid influenza vaccines and respiratory virus combination vaccines
EA201690115A1 (ru) Комбинированные иммуногенные композиции
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
CL2013002631A1 (es) Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura.
MX2018012858A (es) Metodo mejorado para producir particulas similares a virus.
MX2022015398A (es) Virus sincitial respiratorio atenuado vivo.